Syndax Pharmaceuticals (SNDX) is back in focus after new data from its Phase 1/2 SAVE trial, which is testing an all-oral Revuforj-based regimen in relapsed or refractory acute myeloid leukemia, reached leading hematology platforms.

The SAVE trial update arrives after a mixed year for Syndax Pharmaceuticals, with the stock’s latest share price at $19.00, a 1-year total shareholder return of about 100%, but a 90-day share price return that has fallen 21%. This hints that momentum has cooled in the short term despite stronger longer term gains.

If this kind of trial-driven move has your attention, it could be a good moment to scan other potential opportunities in healthcare using the 38 healthcare AI stocks

With Syndax Pharmaceuticals trading at $19.00, an indicated intrinsic discount of about 87%, and analyst targets around $39.00, you have to ask: is the stock still undervalued or already pricing in future growth?

Most Popular Narrative: 51.9% Undervalued

At $19.00, the most followed narrative on Syndax Pharmaceuticals pegs fair value at about $39.50, framing the stock as materially below that estimate.

Late-stage pipeline advancements (including frontline trials, lifecycle management, and expansion into new indications like IPF for Niktimvo), coupled with strong clinical data and market-leading positions in precision oncology, provide robust long-term growth avenues aligned with surging demand for targeted therapies, supporting sustained multi-year earnings momentum.

Curious what kind of revenue ramp, margin shift, and future earnings multiple are baked into that fair value estimate? The underlying forecast blends rapid top line growth with a profitability profile more commonly associated with mature, cash generative pharma players, all condensed into a single valuation story.

Result: Fair Value of $39.50 (UNDERVALUED)

However, Syndax Pharmaceuticals is still heavily tied to just two late-stage drugs, so any clinical or regulatory setback, or slower uptake than expected, could quickly challenge that undervalued story.

Next Steps

Given the mix of optimism and caution around Syndax Pharmaceuticals, it makes sense to review the underlying data yourself and decide quickly where you stand based on the 2 key rewards.

Looking for more investment ideas beyond Syndax Pharmaceuticals?

If Syndax Pharmaceuticals has sharpened your focus on where capital goes next, do not sit on the sidelines while other opportunities line up across different corners of the market.

• Target potential mispricing by scanning companies flagged as 45 high quality undervalued stocks before others connect the dots.
• Prioritize resilience by reviewing the solid balance sheet and fundamentals stocks screener (48 results) and focus on stocks backed by stronger finances.
• Get ahead of the crowd by checking the screener containing 19 high quality undiscovered gems that most investors are still overlooking.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.